

Chapter 5

Role of Overall Treatment Time in Radiotherapy Management of H&N Cancer

1 Background

It is well understood that prolongation of treatment time reduces overall survival & local control and reason behind is the rapid repopulation in early responding tissues (tumor, skin & mucosa). Repopulation decreases radiosensitivity in tumor and normal tissue as number of surviving target cell increases during treatment period. The onset of repopulation in tumor and normal tissue occurs within the first week after radiotherapy initiated. To consider repopulation effect overall treatment time (OTT) is an indirect way to measure it. Jose *et al.* explained in his study how prolonging overall treatment time negatively affect local control and overall survival (González Ferreira *et al.* 2015). Number of clinical trials and various studies showed that shortening the overall treatment time by means of altered fractionation or accelerated fractionation resulted in improvement of overall survival and loco-regional control in head & neck cancers as well as aggravation of early radiation induced toxicity.(Lacas *et al.* 2017; Overgaard *et al.* 2003). With modern radiotherapy equipment it is possible to achieve treatment delivery accuracy which boosted confidence among clinicians to practice hypo- fractionated treatment schedules in head & neck cancers. Besides this moderately hypo-fractionated schedules reduces overall treatment time (OTT). Accelerated fractionation schedules (AFS) is also an available alternative for shortening OTT.

Treatment plans evaluation of fractionation schedules other than conventional fractionation needs to be assessed differently in view of tumour control probability (TCP) and normal tissue complication probability (NTCP). Radiobiological (RB) model based calculation of TCP and NTCP needs attention in altered fractionation schedules. In order to compare the expected biological effect of different fractionation schedules biological effective dose (BED) term is introduced, it is used in isoeffective dose calculation (Fowler 2010). The repopulation correction factor should be included in case of tissues which are rapidly proliferating hence BED equation is modified to compensate repopulation factor presented by equation 2.(Martin, Prise, and Hill 2019) Therefore, it is better to consider BED equation while estimating TCP/NTCP for early or rapidly proliferating tissue.

There are five fundamental mechanisms of fractionated radiotherapy, Redistribution (cell cycle effect), reoxygenation, repair, repopulation and radio sensitivity. Ideally, radiobiological models must incorporate all five mechanisms in their formulation for gaining higher accuracy in determining TCP & NTCP. It can be well appreciated if the existing RB models incorporate all 5Rs of radiotherapy but there are only few models which considered all five factors for estimating TCP & NTCP. Here in this analytical study we chose Niemierko equivalent uniform dose (EUD) model, Poisson model and Lyman Kutcher Berman (LKB) model, as these models are renowned and simple. Radiosensitivity takes care by all RB models because of α/β ratio which is the ratio of cellular radiosensitivity ' α ' to repair capacity ' β '. Repopulation effect can be considered if equivalent dose (EQD2) calculated using time corrected BED formula where OTT assumed. Reoxygenation effect takes care by oxygen enhancement ratio (OER) and this parameter is a part of few RB models formulation. Redistribution (cell cycle effect) is very critical to assess and it is not a part of any existing RB models as far as our knowledge permits. The cell repair effect play very interesting role in altered fractionation and it takes care by the parameter of repair half time ($T_{1/2}$) which is incorporated in some RB models formulation only.

Eric J Hall stated that “fraction size is the dominant factor in determining the late effects; overall treatment has little influence. By contrast fraction size and overall treatment time both determine the response of acutely responding tissue”. This study presented demonstration to analyse how the variation in OTT and fraction size affect the predictions of TCP & NTCP by three radiobiological models for acutely responding tissue in predefined altered fractionation schedules. Late responding tissues are slowly proliferating and assumed to have low α/β ratio hence no correction for overall time is necessary (Fowler 2007).

2 Material and Methods

We intended to demonstrate variation in outcome of TCP & NTCP in moderately hypo fractionated and accelerated fractionation schedules when overall treatment time in days takes under consideration. This can be achieved when we calculate TCP/NTCP by time corrected BED formula and compared against the calculated TCP/NTCP by simple BED formula which do not take into account OTT. The OTT effect exist for early responding tissue therefore TCP/NTCP estimation restricted for tumour and oral mucosa only. The present study separated in two scenario, in first scenario, conventional fractionated schedule (CFS) versus moderately hypo-fractionated schedules compared as shown in table 5.1 & 5.2. In second scenario, CFS versus accelerated fractionation schedule (AFS) compared as shown in table 5.3 & 5.4 referred from DAHANCA clinical trial.(Overgaard *et al.* 2003)

Table 5.1: The table presenting BED, time corrected BED, EQD2 and time corrected EQD2 calculated values for tumor in two different fractionation scenario undertaking parameters as ($\alpha/\beta = 10$, $T_k = 21$ days, $T_p = 3$, $\alpha = 0.35$)

	Conventional	Moderately hypo-fractionation schedules		
	70 Gy/35#	66 Gy/30#	60 Gy/24#	55 Gy/20#
Dose/#	2 Gy/#	2.2 Gy/#	2.5 Gy/#	2.75 Gy/#
BED	84	80.52	75	70.1
EQD2	70.0	67.1	62.5	58.4
TCBED	67.5	68.64	68.40	67.46
TCEQD2	56.25	57.2	57.0	56.21
OTT (T)	46	39	31	25

Table 5.2: The table presenting BED, time corrected BED (TCBED), EQD2 and time corrected EQD2 (TCEQD2) calculated values for oral mucosa in two different fractionation scenario undertaking parameters as ($\alpha/\beta = 10$, $T_k = 7$ days, $T_p = 2.5$, $\alpha = 0.35$)

	Conventional	Moderately hypo-fractionation schedules		
	70 Gy/35#	66 Gy/30#	60 Gy/24#	55 Gy/20#
Dose/#	2 Gy/#	2.2 Gy/#	2.5 Gy/#	2.75 Gy/#
BED	84	80.52	75	70.1
EQD2	70.0	67.1	62.5	58.4
TCBED	53.11	55.18	55.99	55.84
TCEQD2	44.26	45.98	46.66	46.53
OTT	46	39	31	25

Table 5.3: The table presenting BED, time corrected BED, EQD2 and time corrected EQD2 calculated values for conventional and accelerated fractionation schedule of tumor undertaking parameters as ($\alpha/\beta = 10$, $T_k = 21$ days, $T_p = 3$, $\alpha = 0.35$)

	Conventional	Accelerated
	66 Gy/33# (5#/wk)	6#/wk
Dose/#	2 Gy/#	2 Gy/#
BED	79.2	79.2
EQD2	66	66
TCBED	64.02	68.64
TCEQD2	53.35	57.2
OTT	44	37

Table 5.4: The table presenting BED, time corrected BED, EQD2 and time corrected EQD2 calculated values for conventional and accelerated fractionation schedule of oral mucosa undertaking parameters as ($\alpha/\beta = 10$, $T_k = 7$ days, $T_p = 2.5$, $\alpha = 0.35$)

	Conventional	Accelerated
	66 Gy/33# (5#/wk)	6#/wk
Dose/#	2 Gy/#	2 Gy/#
BED	79.2	79.2
EQD2	66	66
TCBED	49.89	55.44
TCEQD2	41.58	46.2
OTT	44	37

2.1. LQ model: The linear-quadratic (LQ) is the fundamental model applied for isoeffective dose calculation and its validity is considered up to 6 Gy per fraction. Beyond this range the dose-response curve keep on bending presenting inconsistency with *in vitro* survival curves. (Williams 2019) Therefore, LQ model is good for low dose approximation and useful for comparing different fractionation schedules. Hence, biological effective dose (BED) term is introduced as shown below.

$$BED = nd (1 + d/(\alpha/\beta)) \quad \text{----- (1)}$$

Where, n and d are the number of fractions and dose per fraction of fractionation schedule α/β is a ratio of linear to quadratic component

The time corrected BED (TC BED) formula which is a modified form of BED formula with an overall time factor included is as given by

$$BED = nd \left(1 + \frac{d}{\alpha/\beta} \right) - \frac{\log_e 2}{\alpha T_p} (T - T_k) \quad \text{----- (2)}$$

Where,

T is overall treatment time in days (with first day = Day 0, not Day 1)

T_k is onset time of kick-off time of repopulation in the tissue of interest

α is a radiosensitivity coefficient of non-repairable damage

T_p is a doubling time of head and neck cancer repopulating cells after T_k

2.2 The equivalent dose (EQD₂) at 2 Gy/fraction is the dose conversion formula when fractionation schedule varies from the conventional fractionation schedule. It can be defined by two different formulas as mentioned below.

$$EQD2 = Di \left(\frac{\frac{\alpha}{\beta} + di}{\frac{\alpha}{\beta} + 2} \right) \text{-----} (3)$$

$$EQD2 = \frac{BED}{\left(1 + \frac{2}{\alpha/\beta}\right)} \text{-----} (4)$$

Where, Di is the total dose and di is the dose per fraction of the reference fractionation schedule.

In present study, 15 patients of head & neck site cancer selected for treatment planning and data acquisition. Present study assumed four fractionation schedules for demonstration purpose as follows conventional fractionation schedule (70Gy/35 #), fractionation schedule 1 (66 Gy/30#), fractionation schedule 2 (60Gy/24#) & fractionation schedule 2 (55Gy/20#). These fractionation schedules are commonly practiced and referred in various studies.(Ermiş *et al.* 2015)(Sharma *et al.* 2017; The Royal College of Radiologists 2019) Four independent volumetric modulated arc (VMAT) treatment plans were generated for four different fractionation schedules for each patient and therefore total 60 treatment plans. The Eclipse treatment planning system (Version 11.3, Varian Medical Systems, Palo Alto) used for planning and dose calculations of all treatment plans. The treatment plan created for CFS is the reference plan for TCP & NTCP comparison amongst the four plans. The rest three plans for each patient were created simply by changing the dose prescription for FS1, FS2 & FS3, means total dose and dose per fraction. No plan optimization and dose calculation have been performed for rest three plans for each patient. In second scenario, conventional fractionation schedule (66Gy/33# with five fractions per week) compared against accelerated fractionation schedule (66Gy/33# with six fractions per week).

For each patient, there are four dose volume histograms (DVH) obtained which is exported in the form of cumulative DVH text file to in-house developed program in MATLAB (Version 2016b) to calculate Equivalent Uniform Dose (EUD), Tumor Control Probability (TCP) and Normal Tissue Complication Probability (NTCP). The program used some coding from Niemierko et al research article.(Gay and Niemierko 2007) This program used to calculate EUD, TCP and NTCP for four different plans of 15 patients by three different radiobiological models Niemierko EUD, Poisson model and Lyman-Kutcher-Burmen (LKB) model in two cases. In first case EQD₂ is calculated by simple BED formula and in second case EQD₂ is calculated by time corrected BED. TCP is calculated for tumour and NTCP calculated for oral mucosa of 15 patients. We chose very basic models commonly used by researchers. LKB is most commonly used model and QUANTEC dose constraints have been validated in various clinical studies.(Kukołowicz 2004; Warkentin *et al.* 2004).

2.3 Statistical Analysis

Statistical analysis was carried out using IBM SPSS for windows, version 20.0. A paired sample t-test applied to asses' statistical significance between calculated TCP & NTCP for two different fractionation schedules. *P-value* ≤0.05 was considered significant for statistical interference.

3 Result

Figure 4.1 represents the mean values of calculated TCP by EUD model for conventional fractionation schedule (CFS), fractionation schedule 1, fractionation schedule 2, and fractionation schedule 3 which is 93, 91, 85.3 & 76.2% respectively showing decreasing trend as dose per fraction increases when simple BED formula incorporated for EQD2 calculation.




Figure 4.1: Box plot represents the TCP calculated by EUD model (Niemierko) employed with BED formula for four different fractionation schedules. The box represents interquartile range (IQR), the black line in mid of box shows median value of data. The whiskers represents maximum and minimum calculated value whereas upper, middle and lower border of box represents the first, median and third quartile respectively.

Figure 4.2 Represents the mean values of calculated TCP by EUD model for conventional fractionation schedule (CFS), fractionation schedule 1, fractionation schedule 2, and fractionation schedule 3 which is 70.4, 73.4, 72.4 & 69.8% respectively when time corrected BED formula incorporated for EQD2 calculation.




Figure 4.2: Box plot represents the TCP calculated by EUD model (Niemierko) employed with time corrected BED formula for four different fractionation schedules. The box represents interquartile range (IQR), the black line in mid of box shows median value of data. The whiskers represents maximum and minimum calculated value whereas upper, middle and lower border of box represents the first, median and third quartile respectively.

Figure 4.3 represents the mean values of calculated NTCP for oral mucosa by EUD model for conventional fractionation schedule (CFS), fractionation schedule 1, fractionation schedule 2, and fractionation schedule 3 which is 46.4, 42.2, 35.5 & 29.6% respectively showing decreasing trend as

dose per fraction increases when simple BED formula incorporated for EQD2 calculation. Similarly mean values of NTCP calculated for oral mucosa by LKB model for CFS, FS1, FS2 & FS3 are 50.25, 48, 45.8 & 42.6% respectively indicating decreasing trend as shown in figure 4.4.




Figure 4.3: Box plot represents the NTCP calculated for oral cavity by EUD model (Niemierko) employed with BED formula for four different fractionation schedules. The box represents interquartile range (IQR), the black line in mid of box shows median value of data. The whiskers represents maximum and minimum calculated value whereas upper, middle and lower border of box represents the first, median and third quartile respectively.




Figure 4.4: Box plot represents the NTCP calculated for oral cavity by LKB model employed with BED formula for four different fractionation schedules. The box represents interquartile range (IQR), the black line in mid of box shows median value of data. The whiskers represents maximum and minimum calculated value whereas upper, middle and lower border of box represents the first, median and third quartile respectively.

Figure 4.5 represents the mean values of calculated NTCP for oral mucosa by EUD model for conventional fractionation schedule (CFS), fractionation schedule 1, fractionation schedule 2, and fractionation schedule 3 which is 11.4, 13.4, 15.3 & 15.8% respectively showing increasing trend as dose per fraction increases when time corrected BED formula incorporated for EQD2 calculation. Similarly mean values of NTCP calculated for oral mucosa by LKB model for CFS, FS1, FS2 & FS3 are 25.3, 27.9, 29.5 & 30% respectively indicating increasing trend as shown in figure 4.6.




Figure 4.5: Box plot represents the NTCP calculated for oral cavity by EUD model (Niemierko) employed with time corrected BED (TC-BED) formula for four different fractionation schedules. The box represents interquartile range (IQR), the black line in mid of box shows median value of data. The whiskers represents maximum and minimum calculated value whereas upper, middle and lower border of box represents the first, median and third quartile respectively.




Figure 4.6: Box plot represents the NTCP calculated for oral cavity by LKB model employed with time corrected BED (TC-BED) formula for four different fractionation schedules. The box represents interquartile range (IQR), the black line in mid of box shows median value of data. The whiskers represents maximum and minimum calculated value whereas upper, middle and lower border of box represents the first, median and third quartile respectively.

The present study compared calculated TCP for tumors by Niemierko EUD model & Poisson model in conventional fractionation schedule (66 Gy in 33 fraction with 5 fraction per week) versus accelerated fractionation schedule (66 Gy in 33 fraction with 6 fraction per week) and observed statistical significant difference ($p < 0.05$). The figure 4.7 & 4.8 represents that calculated TCP by EUD model & Poisson's model for AFS (mean values 72.9 & 73.2) is higher than CFS (mean values 59.6 & 59.3) when time corrected BED formula employed.




Figure 4.7: Box plot represents the TCP calculated by EUD model (Niemierko) employed with time corrected BED formula for accelerated and conventional fractionation schedules. The box represents interquartile range (IQR), the black line in mid of box shows median value of data. The whiskers represents maximum and minimum calculated value whereas upper, middle and lower border of box represents the first, median and third quartile respectively.




Figure 4.8: Box plot represents the TCP calculated by Poisson's model employed with time corrected BED formula for accelerated and conventional fractionation schedules. The box represents interquartile range (IQR), the black line in mid of box shows median value of data. The whiskers represents maximum and minimum calculated value whereas upper, middle and lower border of box represents the first, median and third quartile respectively.

Similarly there is statistically significant difference between ($p < 0.05$) calculated NTCP for oral mucosa by EUD model & LKB model in conventional fractionation schedule (66 Gy in 33 fraction with 5 fraction per week) versus accelerated fractionation schedule (66 Gy in 33 fraction with 6 fraction per week). The figure 4.9 represents that calculated NTCP by EUD model & LKB model for AFS (mean values 18 & 25) is higher than CFS (mean values 11 & 20) when time corrected BED formula incorporated. The above result indicates that TCP & NTCP calculation based on time corrected BED formula can only able to differentiate between CFS & AFS as it takes into account effect of overall treatment time keeping same dose per fraction for both the schedule.




Figure 4.9: Box plot represents the NTCP calculated for oral cavity by EUD model & LKB model employed with time corrected BED formula for accelerated (AFS) and conventional fractionation schedules (CFS). The box represents interquartile range (IQR), the black line in mid of box shows median value of data. The whiskers represents maximum and minimum calculated value whereas upper, middle and lower border of box represents the first, median and third quartile respectively. The blue box indicates NTCP for CFS whereas green box shows NTCP for AFS calculated by EUD model. The grey box indicates NTCP for CFS whereas violet box shows NTCP for AFS calculated by LKB model.

4 Discussion

The present study concentrated to understand the differences observed when OTT takes into account for estimation of TCP and NTCP for early responding tissue (tumor and oral mucosa). In this study four fractionation schedules, designed such that though their dose per fraction and physical doses are different but biological effective doses are approximately equal (maximum difference of 1 Gy) when OTT considered. These fractionation schedules (FS1, FS2 & FS3) are commonly practices, and it provides a trend which helps in comparison. The trend is like that dose per fraction increases and OTT decreases. It is clinically observed that for high dose per fractionation schedules, the relative toxicity for oral mucosa is also more. The calculated NTCP by simple BED formula does not follow and showed reverse trend as shown in fig.4.3 because effect of repopulation in tissue is ignored in calculation hence presenting wrong scenario. In contrast, when repopulation effect takes into account and NTCP calculated based on time corrected BED, the result is in accordance with clinical observation. It is worth to be noted that there is significant drop in NTCP values based on simple BED formula versus time corrected BED formula calculated by both Niemierko & LKB model as shown in figure 4.3,4.4,4.5&4.6. These observations required clinical evidence and author would like to recommend that the individuals must perform clinical validation of radiobiological models when NTCP estimated based on time corrected BED formula.

From the proposed study, it is observed that accuracy in TCP/NTCP estimation is supposed to be compromised when dose per fraction increases against conventional dose per fraction. This may be because the predicted TCP/NTCP based on biological parameters derived from conventional dose per fraction and cannot be assumed that it will represent same underlying biology for higher dose per

fraction. There are some studies which derived biological parameters specific to altered fractionation schedules and expecting more studies in order to build reliable data for the application of radiobiological models in various altered fractionation schedules. Radiation induced oral mucositis can cause treatment interruption for several days which directly impact local tumour control rates due to repopulation of tumor clonogenic cells. Moderately hypo-fractionated treatments schedules improves efficacy outcome of head and neck cancer with a higher incidence of acute effect such as ulcerative mucositis which ultimately result in treatment interruptions.(Dörr 2003; Russo *et al.* 2008; Trott and Kummermehr 1993) Therefore NTCP estimation of oral mucosa required special attention in case of altered fractionation schedules. In case of moderately hypo-accelerated fractionation schedules application of radiobiological models for TCP/NTCP estimation should be avoided or should be implement very cautiously. There could be major difference between the predictive probabilities and observed outcome which is possible because of biological parameters of radiobiological models used in calculation based on conventional dose per fraction regimen and reliability is under the shadow of doubt.

In view of accelerated fractionation schedules, without considering OTT in days will be incorrect for TCP/NTCP prediction. From the table 5.3 & 5.4, it is noted that physical doses for CFS & AFS is equal and difference appears only when time corrected BED incorporated for TCP and NTCP calculation for tumour & oral mucosa. We excluded TCP and NTCP estimation for hyper fractionation schedules because the biological parameters used in the calculations derived with the assumption of one fraction per day and five fractions per week. For considering two fractions per day, the concept of repair half time needs to be addressed carefully. The author is not confident that application of radiobiological models are suitable for hyper-fractionation schedules and it can be limitation of authors view. The concept of repair half time play major role in hyper-fractionation and it is quite complex besides this derived biological input parameters available in literature based on single fraction per day.(Bentzen, Saunders, and Dische 1999) Hyper-fractionation schedules proved their excellence in terms of clinical outcome against conventional and hypo-fractionation schedules in squamous cell carcinoma of head & neck cancer, therefore application of radiobiological models needs to be explore for various altered hyper-fractionation schedules.

The inclusion of time corrected BED in TCP/NTCP estimation is important because during radiotherapy, treatment interruptions are common and there are several reasons machine breakdown, holidays etc. The tumour biological effective dose (BED) reduces by a factor of 0.7 Gy/day after 21 days and in case of acute mucosa it is 0.8 Gy/day after 7 days, including weekends for repopulation.(Trott and Kummermehr 1991, 1993) Hence, in such case predicted TCP and NTCP gets corrected automatically because OTT in days is a part of calculation which is not possible with simple BED formula. Until recently, biological based treatment planning system introduced, manufacturer provided the biological optimization and biological evaluation feature but it should be cautiously use with the knowledge that TCP/NTCP calculation based on time corrected BED or simple BED formula which can significantly affect the outcome.(Allen Li *et al.* 2012)

There are some limitations of the study like fewer radiobiological models applied. As we know that there is differences in the accuracy of TCP/NTCP outcome of various radiobiological models exist in literature. There are several challenges associated with applied radiobiological models like missing data, prediction of multiple complication grades at different times, over fitting and non-linear dose relationship which limits the prediction power of models.(Van den Bosch *et al.* 2020)

5 Conclusion

Here we demonstrated that uncertainty and inaccuracy in TCP/NTCP estimation increases as move away from conventional dose fractionation schedules. The biological input parameters derived from conventional dose fractionation schedules should be cautiously used while calculating NTCP for moderately hypo-fractionation and accelerated fractionation schedules in head & neck cancer. There is significant impact of OTT and it should be considered when evaluating TCP/NTCP for early responding tissue. In present study, role of overall treatment time in accelerated fractionation and altered fractionation regimens demonstrated. Overall treatment time (OTT) plays significant role while assessing toxicity in early responding tissue and OTT affects the tumor control probability. Therefore without considering OTT, estimation of TCP and NTCP is prone to error. Author suggested that use of time corrected biological effective dose (BED) formula must be incorporated in TCP and NTCP calculation to account for OTT effect. The developed program have provision to calculate TCP and NTCP with and without OTT effect.

References

- Allen Li, X., Markus Alber, Joseph O. Deasy, Andrew Jackson, Kyung Wook Ken Jee, Lawrence B. Marks, Mary K. Martel, Charles Mayo, Vitali Moiseenko, Alan E. Nahum, Andrzej Niemierko, Vladimir A. Semenenko, and Ellen D. Yorke. 2012. "The Use and QA of Biologically Related Models for Treatment Planning: Short Report of the TG-166 of the Therapy Physics Committee of the AAPM." *Medical Physics* 39(3):1386–1409.
- Bentzen, Søren M., Michele I. Saunders, and Stanley Dische. 1999. "Repair Halftimes Estimated from Observations of Treatment-Related Morbidity after CHART or Conventional Radiotherapy in Head and Neck Cancer." *Radiotherapy and Oncology* 53(3):219–26.
- Van den Bosch, Lisa, Ewoud Schuit, Hans Paul van der Laan, Johannes B. Reitsma, Karel G. M. Moons, Roel J. H. M. Steenbakkers, Frank J. P. Hoebbers, Johannes A. Langendijk, and Arjen van der Schaaf. 2020. "Key Challenges in Normal Tissue Complication Probability Model Development and Validation: Towards a Comprehensive Strategy." *Radiotherapy and Oncology* 148:151–56.
- Dörr, W. 2003. "Modulation of Repopulation Processes in Oral Mucosa: Experimental Results." *International Journal of Radiation Biology* 79(7):531–37.
- Ermiş, Ekin, Mark Teo, Karen E. Dyker, Chris Fosker, Mehmet Sen, and Robin J. D. Prestwich. 2015. "Definitive Hypofractionated Radiotherapy for Early Glottic Carcinoma: Experience of 55Gy in 20 Fractions." *Radiation Oncology* 10(1).
- Fowler, J. F. 2007. "Is There an Optimum Overall Time for Head and Neck Radiotherapy? A Review, with New Modelling." *Clinical Oncology* 19(1):8–22.
- Fowler, Jack F. 2010. "21 Years of Biologically Effective Dose." *British Journal of Radiology* 83(991):554–68.
- Gay, Hiram A. and Andrzej Niemierko. 2007. "A Free Program for Calculating EUD-Based NTCP and TCP in External Beam Radiotherapy." *Physica Medica* 23(3–4):115–25.
- González Ferreira, José A., Javier Jaén Olasolo, Ignacio Azinovic, and Branislav Jeremic. 2015. "Effect of Radiotherapy Delay in Overall Treatment Time on Local Control and Survival in Head and Neck Cancer: Review of the Literature." *Reports of Practical Oncology and Radiotherapy* 20(5):328–39.
- Kukolowicz, Pawel. 2004. "Clinical Aspects of Normal Tissue Complication Probability." *Reports of Practical Oncology and Radiotherapy* 9(6):261–67.
- Lacas, Benjamin, Jean Bourhis, Jens Overgaard, Qiang Zhang, Vincent Grégoire, Matthew Nankivell, Björn Zackrisson, Zbigniew Szutkowski, Rafal Suwinski, Michael Poulsen, Brian O'Sullivan, Renzo Corvò, Sarbani Ghosh Laskar, Carlo Fallai, Hideya Yamazaki, Werner Dobrowsky, Kwan Ho Cho, Adam S. Garden, Johannes A. Langendijk, Celia Maria Pais Viegas, John Hay, Mohamed Lotayef, Mahesh K. B. Parmar, Anne Aupérin, Carla van Herpen, Philippe Maingon, Andy M. Trotti, Cai Grau, Jean Pierre Pignon, Pierre Blanchard, Jacques Bernier, Quynh Thu Le, Andy Trotti, Jai Prakash Agarwal, Kian K. Ang, Hassan K. Awwad, Almalina Bacigalupo, Harry Bartelink, Ellen Benhamou, Wilfried Budach, Imjai Chitapanarux, Laurence Collette, Carla Dani, Stanley Dische, James W. Denham, Chantal ML Driessen, Sushmita Ghoshal, Vincent Gregoire, John H. Hay, Andrzej Hliniak, Jørgen Johansen, Claus Andrup Kristiansen, Valentina Krstevska, Michel Lapeyre, Boguslaw Maciejewski, Wojciech Michalski, Sung Ho Moon, Per Nilsson, Patrizia Olmi, Kinji Nishiyama, Michael G. Poulsen, Kunnambath Ramadas, Anupam Rishi, David I. Rosenthal, Giuseppe Sanguineti, Michele I. Saunders, Christian Sire, Krzysztof Skladowski, Luis Souhami, Nitin Tandon, Harm van Tinteren, Valter Torri, Lee Tripcony, John Waldron, Joachim Widder, Stuart Wong, and Jonn S. Wu. 2017. "Role of Radiotherapy Fractionation in Head and Neck Cancers (MARCH): An Updated Meta-Analysis." *The Lancet Oncology* 18(9):1221–37.
- Martin, Stewart, Kevin M. Prise, and Mark A. Hill. 2019. "Pushing the Frontiers of Radiobiology: A Special Feature in Memory of Sir Oliver Scott and Professor Jack Fowler." *British Journal of Radiology* 92(1093):1–10.
- Overgaard, Jens, Hanne Sand Hansen, Lena Specht, Marie Overgaard, Cai Grau, Elo Andersen, Jens Bentzen, Lars Bastholt, Olfred Hansen,

- Jørgen Johansen, Lisbeth Andersen, and Jan F. Evensen. 2003. "Five Compared with Six Fractions per Week of Conventional Radiotherapy of Squamous-Cell Carcinoma of Head and Neck: DAHANCA 6&7 Randomised Controlled Trial." *Lancet* 362(9388):933–40.
- Russo, Gregory, Robert Haddad, Marshall Posner, and Mitchell Machtay. 2008. "Radiation Treatment Breaks and Ulcerative Mucositis in Head and Neck Cancer." *The Oncologist* 13(8):886–98.
- Sharma, Neeraj, R. K. Spartacus, Aseem Rai Bhatnagar, Kartick Rastogi, R. K. Panday, Rohitashwa Dana, Sandeep Jain, and Sandeep Bhaskar. 2017. "Hypofractionated Accelerated Radiotherapy Compared with Conventional Radiotherapy of Squamous Cell Carcinoma of Head and Neck with Concurrent Cisplatin ." *16(6):80–83.*
- The Royal College of Radiologists. 2019. "Radiotherapy Dose Fractionation, Third Edition." *Clinical Oncology* (December):17.
- Trott, K. R. and J. Kummermehr. 1991. "Rapid Repopulation in Radiotherapy: A Debate on Mechanism. Accelerated Repopulation in Tumours and Normal Tissues." *Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology* 22(3):159–60.
- Trott, Klaus Rüdiger and Johann Kummermehr. 1993. "The Time Factor and Repopulation in Tumors and Normal Tissues." *Seminars in Radiation Oncology* 3(2):115–25.
- Warkentin, Brad, Pavel Stavrev, Nadia Stavreva, Colin Field, and B. Gino Fallone. 2004. "A TCP-NTCP Estimation Module Using DVHs and Known Radiobiological Models and Parameter Sets." *Journal of Applied Clinical Medical Physics* 5(1):50–63.
- Williams, Jacqueline. 2019. "Basic Clinical Radiobiology." *International Journal of Radiation Biology* 95(6):797–797.